Nektar, Piper Sandler
Piper Sandler Issues Overweight Rating for Nektar Therapeutics (NKTR) Stock
On Monday, Nektar Therapeutics (NKTR) stock saw a modest uptick, ending the day at $1.33 which represents a slight increase of $0.10 or 8.13% from the prior close of $1.23. The stock opened at $1.37 and touched a low of $1.
GlobalData on MSN17h
Nektar Therapeutics to sell Alabama facility to AmpersandThe transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.
After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...
Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the company’s lead asset ...
(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...
Nektar Therapeutics is selling off its only manufacturing facility as well as its reagent business to private equity firm Ampersand Capital Partners for $90 million. In the deal, which is ...
Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...
Nektar Therapeutics had a negative net margin of 190.09% and a negative return on equity of 133.64%. During the same quarter in the prior year, the firm earned ($0.27) earnings per share.
Short interest in Nektar Therapeutics (NASDAQ:NKTR) decreased during the last reporting period, falling from 7.76M to 7.31M. This put 5.08% of the company's publicly available shares short.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback